Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

KIO-201

Other · developed by Kiora Pharmaceuticals

Phase 2 Most advanced trial (none active)
KPRX Developer
1 Registered trials

What is KIO-201?

KIO-201 is a stand-alone therapy that forms a barrier on the ocular surface, reducing mechanical lid friction and protecting the cornea from repeat injury. It is studied in persistent corneal epithelial defects.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Ophthalmology
Developer
Kiora Pharmaceuticals, Inc. (KPRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05436288 Phase 2 Persistent Corneal Epithelial Defect Completed KPRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Persistent Corneal Epithelial Defect

More from Kiora Pharmaceuticals

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KPRX page.

Follow KPRX, the company behind KIO-201

See KPRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KPRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.